Latest news

• Pfizer posts positive Trumenba vaccine data

  Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials. ... Trumenba was approved by the FDA in 2014 to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B.

• Pfizer gets FDA nod for meningitis vaccine Trumenba

  Trumenba - formerly known as rLP2086 - has been approved by the FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people aged 10 to 25, a strain which ... Invasive meningococcal disease is a life-threatening

• US panel backs pneumococcal vaccines for seniors

  The ACIP recommendations now go to the Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) for review and approval. ... Separately, Pfizer also said that the FDA has accepted its marketing application for

• Pfizer's meningitis vaccine 'a breakthrough'

  Aside from the risk of death, meningococcal B disease can also lead to long-term disabilities such as brain damage and hearing loss. ... The breakthrough therapy designation highlights the urgent need for prevention of meningococcal B disease," he added.

• Research into meningococcal B disease

  Research into meningococcal B disease. The first approved vaccine represents a major success for meningococcal B research efforts. ... Looking ahead. Vaccines against serotype B meningococcal disease have proved difficult to produce, and require a